UNSPSC 51183708: Rosiglitazone maleate

This classification denotes a vasodilator agent, fibrinolytic agent, and hypoglycemic agent with the molecular formula C18H19N3O3S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KX2339DP44, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)- but more generally known as rosiglitazone maleate, which bears US NIH Compound Identifier 77999.

UNSPSC 51183708 Rosiglitazone maleate is a Commodity code representing a specific oral antidiabetic pharmaceutical product. State and local governments procure this drug through cooperative purchasing agreements that bundle it with broader generic pharmaceutical catalogs rather than as a standalone line item. The work involves manufacturers and branded suppliers contracting to supply NDC-specific products at negotiated pricing to authorized wholesalers serving state agencies, counties, municipalities, and other public healthcare facilities. Issuing bodies are predominantly multistate cooperative purchasing alliances and state health or procurement departments that aggregate demand across member jurisdictions to achieve volume discounts and standardized supply chain management.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating states including Minnesota and Oregon. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain compliance with cGMP and DSCSA requirements, hold minimum insurance coverage including $5 million commercial general liability, and accept a 3 percent administrative fee on all purchases. Pricing evaluation weights 75 percent on price competitiveness with 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and fee acceptance. Products must be available by May 15, 2026, with contract effectiveness July 1, 2026, and a two-year initial term. No specific award values or set-aside designations appear in the available documentation.